Compare GSUN & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSUN | REVB |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | China | United States |
| Employees | N/A | 9 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.9M |
| IPO Year | 2020 | N/A |
| Metric | GSUN | REVB |
|---|---|---|
| Price | $0.38 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.0M | 46.3K |
| Earning Date | 02-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.47 |
| 52 Week High | $3.31 | $2.93 |
| Indicator | GSUN | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 42.76 |
| Support Level | $0.35 | $0.96 |
| Resistance Level | $0.57 | $1.21 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 56.88 | 22.22 |
Golden Sun Technology Group Ltd operates two principal lines of business: tutorial services and e-commerce services. The company's e-commerce operations currently consist of data analytics-driven marketing and social media promotional services for small and medium-sized businesses on short video platforms based in China. The company's education centers offer two main programs, comprising of foreign language tutorial programs in less commonly taught languages, including, among other things, Spanish and Japanese, provided to individual students as well as to companies and other organizations; and Gaokao repeater tutorial programs, provided to individual students.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.